Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China

[PR Newswire] – Under the agreement, Sanofi will invest US$80 million in newly issued JHL shares at NT$90 per share. In addition, Sanofi will make an upfront payment of US$21 million to acquire exclusive rights for the proposed biosimilar of Rituximab and options to certain JHL pipeline products. JHL will lead the development, registration, and manufacturing activities while Sanofi will lead commercialization efforts in China. http://finance.yahoo.com/news/sanofi-jhl-biotech-announce-strategic-000000327.html